Clinical Trial Update: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SHR-3032 in Healthy Subjects [Phase 1]

View source ↗

Summary

Phase 1 study of SHR-3032 in healthy subjects completed to assess safety, tolerability, pharmacokinetics and pharmacodynamics for potential use in preventing gr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Organ Transplant Rejection

Drugs mentioned

• SHR-3032

Snippet

Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd | Conditions: Prevention of Graft Rejection After Organ Transplantation | Phase 1 | Status: COMPLETED